Straumann Holding AG (SAUHF)
137.83
+4.90
(+3.68%)
USD |
OTCM |
May 17, 16:00
Straumann Enterprise Value: 21.73B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 21.73B |
| May 16, 2024 | 20.94B |
| May 15, 2024 | 20.78B |
| May 14, 2024 | 20.41B |
| May 13, 2024 | 20.12B |
| May 10, 2024 | 20.19B |
| May 09, 2024 | 20.38B |
| May 08, 2024 | 20.11B |
| May 07, 2024 | 19.93B |
| May 06, 2024 | 19.73B |
| May 03, 2024 | 20.99B |
| May 02, 2024 | 19.42B |
| May 01, 2024 | 20.53B |
| April 30, 2024 | 21.21B |
| April 29, 2024 | 24.03B |
| April 26, 2024 | 23.14B |
| April 25, 2024 | 22.46B |
| April 24, 2024 | 23.24B |
| April 23, 2024 | 24.84B |
| April 22, 2024 | 22.77B |
| April 19, 2024 | 22.97B |
| April 18, 2024 | 22.44B |
| April 17, 2024 | 23.67B |
| April 16, 2024 | 22.83B |
| April 15, 2024 | 23.53B |
| Date | Value |
|---|---|
| April 12, 2024 | 23.91B |
| April 11, 2024 | 24.49B |
| April 10, 2024 | 23.99B |
| April 09, 2024 | 24.88B |
| April 08, 2024 | 23.50B |
| April 05, 2024 | 23.88B |
| April 04, 2024 | 24.07B |
| April 03, 2024 | 23.75B |
| April 02, 2024 | 24.49B |
| April 01, 2024 | 24.29B |
| March 28, 2024 | 25.40B |
| March 27, 2024 | 25.12B |
| March 26, 2024 | 24.72B |
| March 25, 2024 | 24.37B |
| March 22, 2024 | 24.83B |
| March 21, 2024 | 25.83B |
| March 20, 2024 | 24.73B |
| March 19, 2024 | 25.52B |
| March 18, 2024 | 24.78B |
| March 15, 2024 | 25.44B |
| March 14, 2024 | 26.21B |
| March 13, 2024 | 26.41B |
| March 12, 2024 | 26.02B |
| March 11, 2024 | 26.11B |
| March 08, 2024 | 26.93B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
9.063B
Minimum
Mar 19 2020
35.47B
Maximum
Nov 09 2021
20.18B
Average
19.42B
Median
Jul 13 2022
Enterprise Value Benchmarks
| AC Immune SA | 198.33M |
| CRISPR Therapeutics AG | 2.666B |
| Addex Therapeutics Ltd | 4.792M |
| NLS Pharmaceutics Ltd | 7.841M |
| Molecular Partners AG | -98.31M |
Enterprise Value Related Metrics
| Earnings Yield | 1.25% |
| Operating Earnings Yield | 2.09% |
| Normalized Earnings Yield | 1.246 |